Related Experiment Video
Updated: Jun 12, 2026

Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models
Published on: May 17, 2024
The hand-foot-syndrome associated with medical tumor therapy - classification and management
Annette Degen1, Mareike Alter, Florian Schenck
1Clinic and Polyclinic for Dermatology, and Allergy, Skin Cancer Center Hannover (HTZH), Hannover Medical School, Germany.
Abstract:
The hand-foot-syndrome (HFS, palmoplantar erythrodysesthesia, chemotherapy-associated acral erythema) is characterized by painful predominantly palmo-plantar lesions. The association with different chemotherapeutic agents has been known for over 20 years. More recently, HFS has been reported in association with regimens using targeted agents, in particular the multikinase inhibitors (MKI) sorafenib and sunitinib. The HFS associated with MKI has a different distribution and clinical appearance than the traditional disorder. In this review, similarities and differences between chemotherapy- and MKI-associated HFS are discussed and current recommendations for their prophylaxis and management are summarized.
Related Concept Videos
Diabetic Foot Ulcer
Peripheral Artery Disease IV: Nursing Management
Tumor Immunotherapy
Nephrotic Syndrome II : Assessment and Medical Management
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
